MedTrace Logo

informCLL™: A Disease Registry for Patients With Chronic Lymphocytic Leukemia

NCT02582879 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1504

Last updated 2022-07-22

No results posted yet for this study

Summary

The study is designed as a multicenter, prospective, observational registry of CLL/SLL patients who are initiating approved oral kinase inhibitors, BCL-2 inhibitors or other approved anti-CLL therapies/regimens. The study will characterize treatment patterns and their association with patient characteristics, healthcare resource utilization, and clinical outcomes, as well as patient-reported outcome (PRO) measures.

Conditions

  • Chronic Lymphocytic Leukemia (CLL)

Sponsors & Collaborators

  • Janssen, LP

    collaborator INDUSTRY

  • Pharmacyclics LLC.

    lead INDUSTRY

Principal Investigators

  • Alex Young · Pharmacyclics LLC.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-30
Primary Completion
2021-07-21
Completion
2021-07-21

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02582879 on ClinicalTrials.gov